Health
Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Noosa News24 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
Noosa News19 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General24 hours agoIranian supreme leader makes first public appearance since war with Israel
-
General21 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out